Evaluation of bromelain and temozolomide synergistic combination in human glioblastoma cells

Amini A, Masoumi-Moghaddam S, Ehteda A, Morris DL (2014) Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy. J Exp Clin Cancer Res 33(1):92

Bhui K, Tyagi S, Srivastava AK, Singh M, Roy P, Singh R, Shukla Y (2012) Bromelain inhibits nuclear factor kappa-B translocation, driving human epidermoid carcinoma A431 and melanoma A375 cells through G2/M arrest to apoptosis. Mol Carcinog 51(3):231–243

Birzu C, French P, Caccese M, Cerretti G, Idbaih A, Zagonel V, Lombardi G (2020) Recurrent glioblastoma: from molecular landscape to new treatment perspectives. Cancers 13(1):47

Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM (2002) Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8(8):2725–2734

Brandner S, McAleenan A, Kelly C, Spiga F, Cheng HY, Dawson S, Schmidt L, Faulkner CL, Wragg C, Jefferies S, Higgins JP, Kurian KM (2021) MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane systematic review. Neuro Oncol 23(9):1457–1469

Chang TC, Wei PL, Makondi PT, Chen WT, Huang CY, Chang YJ (2019) Bromelain inhibits the ability of colorectal cancer cells to proliferate via activation of ROS production and autophagy. PLoS ONE 14(1):e0210274

Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947

Dhandayuthapani S, Perez HD, Paroulek A, Chinnakkannu P, Kandalam U, Jaffe M, Rathinavelu A (2012) Bromelain-induced apoptosis in GI-101A breast cancer cells. J Med Food 15(4):344–349

Eda T, Okada M, Ogura R, Tsukamoto Y, Kanemaru Y, Watanabe J, On J, Aoki H, Oishi M, Takei N, Fujii Y, Natsumeda M (2022) Novel repositioning therapy for drug-resistant glioblastoma: in vivo validation study of clindamycin treatment targeting the mTOR pathway and combination therapy with temozolomide. Cancers 14(3):770

Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495–516

Gautam M, Gabrani R (2022) Combinatorial effect of temozolomide and naringenin in human glioblastoma multiforme cell lines. Nutr Cancer 74:1071–1078

Gokoglu N, Yerlikaya P, Ucak I, Yatmaz HA (2017) Effect of bromelain and papain enzymes addition on physicochemical and textural properties of squid (Loligo vulgaris). J Food Meas Charact 11:347–353

Hanif F, Perveen K, Jawed H, Ahmed A, Malhi SM, Jamall S, Simjee SU (2014) N-(2-hydroxyphenyl)acetamide (NA-2) and temozolomide synergistically induce apoptosis in human glioblastoma cell line U87. Cancer Cell Int 14(1):133

Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Tan TC, Sommer C, Bamberg M, Reifenberger G, Weller M (2006) Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24(27):4412–4417

Hikisz P, Bernasinska-Slomczewska J (2021) Beneficial properties of bromelain. Nutrients 13(12):4313

Horibata S, Vo TV, Subramanian V, Thompson PR, Coonrod SA (2015) Utilization of the soft agar colony formation assay to identify inhibitors of tumorigenicity in breast Cancer cells. J Vis Exp 99:e52727

Jasek-Gajda E, Jurkowska H, Jasińska M, Litwin JA, Lis GJ (2019) Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells. Apoptosis 24(11–12):849–861

Kirstein A, Schmid TE, Combs SE (2020) The role of miRNA for the treatment of MGMT unmethylated glioblastoma Multiforme. Cancers 12(5):1099

Lee SW, Kim HK, Lee NH, Yi HY, Kim HS, Hong SH, Hong YK, Joe YA (2015) The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Cancer Lett 360(2):195–204

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402–408

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251

Milani R, Brognara E, Fabbri E, Finotti A, Borgatti M, Lampronti I, Marzaro G, Chilin A, Lee KK, Kok SH, Chui CH, Gambari R (2018) Corilagin induces high levels of apoptosis in the temozolomide-resistant T98G glioma cell line. Oncol Res 26(9):1307–1315

Murthy SS, Narsaiah TB (2021) Cytotoxic effect of bromelain on HepG2 hepatocellular carcinoma cell line. Appl Biochem Biotechnol 193(6):1873–1897

Oliveira E, Bértolo E, Núñez C, Pilla V, Santos HM, Fernández-Lodeiro J, Fernández-Lodeiro A, Djafari J, Capelo JL, Lodeiro C (2017) Green and red fluorescent dyes for translational applications in imaging and sensing analytes: a dual-color flag. ChemistryOpen 7(1):9–52

Osuka S, van Meir EG (2017) Overcoming therapeutic resistance in glioblastoma: the way forward. J Clin Investig 127:415–426

Pazhouhi M, Sariri R, Khazaei MR, Moradi MT, Khazaei M (2018) Synergistic effect of temozolomide and thymoquinone on human glioblastoma multiforme cell line (U87MG). J Cancer Res Ther 14(5):1023–1028

Qi Q, Liu X, Li S, Joshi HC, Ye K (2013) Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth. Acta Pharmacol Sin 34(7):930–938

Rathnavelu V, Alitheen NB, Sohila S, Kanagesan S, Ramesh R (2016) Potential role of bromelain in clinical and therapeutic applications. Biomed Rep 5(3):283–288

Stoyanov GS, Lyutfi E, Georgieva R, Georgiev R, Dzhenkov DL, Petkova L, Ivanov BD, Kaprelyan A, Ghenev P (2022) Reclassification of glioblastoma multiforme according to the 2021 World Health Organization classification of central nervous system tumors: a single institution report and practical significance. Cureus 14(2):e21822

Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E, Barcia J, Guzmán M, Velasco G (2011) A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10(1):90–103

Tysnes BB, Maurer HR, Porwol T, Probst B, Bjerkvig R, Hoover F (2001) Bromelain reversibly inhibits invasive properties of glioma cells. Neoplasia 3(6):469–479

Valtorta S, Lo Dico A, Raccagni I, Gaglio D, Belloli S, Politi LS, Martelli C, Diceglie C, Bonanomi M, Ercoli G, Vaira V, Ottobrini L, Moresco RM (2017) Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models. Oncotarget 8(68):113090–113104

Vollmann-Zwerenz A, Leidgens V, Feliciello G, Klein CA, Hau P (2020) Tumor cell invasion in glioblastoma. Int J Mol Sci 21(6):1932

Wang Y, Kong X, Guo Y, Wang R, Ma W (2017) Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients. Medicine 96(10):e6261

Xiao ZZ, Wang ZF, Lan T, Huang WH, Zhao YH, Ma C, Li ZQ (2020) Carmustine as a supplementary therapeutic option for glioblastoma: a systematic review and meta-analysis. Front Neurol 11:1036

Xue Q, Cao L, Chen XY, Zhao J, Gao L, Li SZ, Fei Z (2017) High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates. Oncol Lett 13(3):1325–1330

Yi GZ, Huang G, Guo M, Zhang X, Wang H, Deng S, Li Y, Xiang W, Chen Z, Pan J, Li Z, Yu L, Lei B, Liu Y, Qi S (2019) Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. Brain 142(8):2352–2366

Zhu P, Du XL, Lu G, Zhu JJ (2017) Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: a population-based study. Oncotarget 8(27):44015–44031